InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Partridge Andrew John, Directeur Exécutif Commercial. Officer active across 1 company, notably Turning Point Therapeutics, Inc.. Cumulatively, 4 reports have been recorded. Breakdown: 0 buy · 4 sells. Total volume traded: €251k. History available since 14 July 2021. The latest transaction was disclosed on 9 February 2022 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations4 total
▼
221 shares@ US$36.302.8% of flowCommon StockSEC:0001209191-22-008983:0
▼
221 shares@ US$36.302.8% of flowCommon StockSEC:0001209191-22-008983
▼
1,869 shares@ US$74.9047.2% of flowCommon StockSEC:0001209191-21-046809
▼
1,869 shares@ US$74.9047.2% of flowCommon StockSEC:0001209191-21-046809:0
4 of 4 declarations
About Partridge Andrew John
Andrew John Partridge is the EVP & Chief Commercial Officer at Turning Point Therapeutics, Inc. He oversees the company's commercial initiatives and plays a key role in developing strategies to drive growth.
